Upstream Bio is advancing UPB-101, a fully human IgG1 monoclonal antibody that binds the TSLP receptor to inhibit signaling in allergic and inflammatory diseases. UPB-101 has completed a first-in-human Phase 1 single-dose escalation in healthy volunteers that was considered safe and well-tolerated, and a Phase 1b multiple ascending dose study in people with asthma is underway. Preclinical data showed inhibition of cytokine production from CD4+ T cells and ILC2 and complete suppression of skin allergic reactions in a monkey model. The company’s IND has been cleared by the FDA to pursue Phase 2 programs in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), and Upstream plans registrational Phase 2 trials in both indications. In parallel with Phase 2, Upstream will conduct translational, manufacturing and device development activities to enable a swift transition to Phase 3. The company also reported data supporting a differentiated dosing regimen of at least every 12 weeks; the new capital is intended to fund the next stage of clinical development and support regulatory, market access and commercialization preparation. Upstream Bio launched with a $200 million Series A to advance its lead program UPB-101, a clinical-stage monoclonal antibody that inhibits the TSLP receptor. UPB-101 was acquired from Astellas after completion of initial clinical and preclinical studies, and the company has selected asthma as the first indication for development. Upstream plans to pursue additional TSLP-mediated inflammatory diseases and to build a pipeline of assets addressing immune-mediated diseases. The company emphasizes that inhibiting TSLP signaling is a validated mechanism positioned upstream of targets such as IL-4, IL-5, IL-13, IL-17 and IgE, which could allow a single treatment to impact multiple pathological processes. The Series A was led jointly by OrbiMed and Maruho Co., Ltd., with participation from Access Biotechnology, Decheng Capital, HBM Healthcare Investments, TCG X, Omega Funds, Samsara BioCapital and Altshuler Shaham Provident Funds Ltd., providing capital to advance clinical development. Upstream is led by an experienced executive team including CEO Samantha Truex and CMO Aaron Deykin, who will lead translational and development efforts.

Total raised

$400M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2023